We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-7.65%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$348M
AUM Growth
-$53.9M
Cap. Flow
+$6.12M
Cap. Flow %
1.76%
Top 10 Hldgs %
74.9%
Holding
26
New
2
Increased
2
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$18.5M
2
TYRA icon
Tyra Biosciences
TYRA
+$6.1M
3
GHRS icon
GH Research
GHRS
+$2.92M
4
VRDN icon
Viridian Therapeutics
VRDN
+$2.48M

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$10.7M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.24M
3
IRON icon
Disc Medicine
IRON
+$2.5M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
1
Enliven Therapeutics
ELVN
$4.15B
$70.5M 20.29%
5,160,975
-637,500
-11% -$10.7M
TRDA icon
2
Entrada Therapeutics
TRDA
$282M
$69.7M 20.04%
4,408,379
– –
IRON icon
3
Disc Medicine
IRON
$2.93B
$20.6M 5.93%
438,442
-50,000
-10% -$2.5M
DNTH icon
4
Dianthus Therapeutics
DNTH
$5.8B
$20.1M 5.79%
+1,472,264
New +$18.5M
MLTX icon
5
MoonLake Immunotherapeutics
MLTX
$1.48B
$17.9M 5.14%
313,210
-44,276
-12% -$2.44M
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.89B
$13.7M 3.96%
462,286
-400,000
-46% -$8.24M
VOR icon
7
Vor Biopharma
VOR
$1.16B
$13.5M 3.88%
318,086
– –
PHVS icon
8
Pharvaris
PHVS
$2.25B
$12.3M 3.53%
587,600
– –
RLYB icon
9
Rallybio
RLYB
$84.6M
$12.2M 3.52%
453,841
– –
ZNTL icon
10
Zentalis Pharmaceuticals
ZNTL
$331M
$9.83M 2.83%
490,000
– –
SCPH
11
DELISTED
scPharmaceuticals
SCPH
$8.55M 2.46%
1,200,647
– –
CLDX icon
12
Celldex Therapeutics
CLDX
$2.96B
$8.54M 2.46%
310,270
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.39M 2.41%
192,500
– –
COGT icon
14
Cogent Biosciences
COGT
$6.64B
$7.71M 2.22%
790,440
– –
VKTX icon
15
Viking Therapeutics
VKTX
$3.8B
$6.48M 1.86%
585,000
– –
ANAB icon
16
AnaptysBio
ANAB
$1.59B
$6.42M 1.85%
357,733
– –
VRDN icon
17
Viridian Therapeutics
VRDN
$2.13B
$6.29M 1.81%
410,000
+130,000
+46% +$2.48M
ARVN icon
18
Arvinas
ARVN
$520M
$6.28M 1.81%
320,000
– –
TYRA icon
19
Tyra Biosciences
TYRA
$1.91B
$5.67M 1.63%
+411,450
New +$6.1M
SPRB
20
Spruce Biosciences
SPRB
$119M
$5.34M 1.54%
31,520
– –
QTTB icon
21
Q32 Bio
QTTB
$450M
$5.31M 1.53%
251,996
– –
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$4.25M 1.22%
665,555
– –
GHRS icon
23
GH Research
GHRS
$1.93B
$4.06M 1.17%
404,404
+252,382
+166% +$2.92M
MRSN
24
DELISTED
Mersana Therapeutics
MRSN
$1.66M 0.48%
52,200
– –
IMPL
25
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$1.24M 0.36%
2,884,791
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q3 2023 Portfolio in Review

As of Q3 2023, 5AM Venture Management held 26 positions worth $348M, down 13% from $401M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

5AM Venture Management's Q3 2023 filing shows 2 new, 2 increased and 4 reduced positions. Its largest new stake was Dianthus Therapeutics: 1,472,264 shares worth $20.1M. The largest sale was Enliven Therapeutics, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q3 2023 buy was Dianthus Therapeutics: 1,472,264 shares worth $20.1M.
  • 5AM Venture Management added most to GH Research in Q3 2023, an estimated $2.92M increase.
  • 5AM Venture Management's biggest Q3 2023 reduction was Enliven Therapeutics, cutting an estimated $10.7M.
  • 5AM Venture Management's ten largest holdings make up 75% of its $348M portfolio in Q3 2023.
  • 5AM Venture Management opened 2 new positions and closed 0 in Q3 2023.
  • 5AM Venture Management's portfolio value fell 13% quarter-over-quarter to $348M.

Based on 5AM Venture Management's 13F filing for Q3 2023, filed 14 Nov 2023.